Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Dose-Escalation Study of GSK2126458 (FTIH)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00972686
First received: September 3, 2009
Last updated: February 26, 2015
Last verified: August 2014
History of Changes
  Purpose

P3K112826 is a Phase I, first-time-in-human dose escalation study in subjects with refractory malignancy. The primary objective of this study is to determine the recommended Phase II dose of GSK2126458 based on safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary evidence of clinical activity. Secondary objectives are to characterize the pharmacokinetics of GSK2126458; and to explore relationships between GSK2126458 pharmacokinetics, pharmacodynamics, response prediction biomarkers and clinical endpoints.


Condition Intervention Phase
Solid Tumours
 Drug: GSK2126458
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Adverse events (AEs) and changes in laboratory values and vital signs. Pharmacokinetic parameter values for GSK2126458, Change from baseline in protein markers in tumor and/or blood. Blood glucose and insulin levels. Tumor response, RECIST defined [ Time Frame: Subjects continue on study until disease progression or consent withdrawal ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Metabolic profile in plasma at the maximum tolerated dose [ Time Frame: Subjects continue on study until disease progression or consent withdrawal ] [ Designated as safety issue: Yes ]
Estimated Enrollment: 150
Study Start Date: November 2009
Estimated Study Completion Date: December 2015
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GSK2126458
GSK2126458 will be dosed continuously (every day) for the duration a 28 day cycle. The 28 day cycles will continue until the subjects withdraw from the study.
 Drug: GSK2126458
GSK2126458 is an experimental treatment for patients with cancer.

Detailed Description:

This study is a Phase I, first-time-in-human dose escalation study in subjects with refractory solid tumors or lymphoma. The primary objective of this study is to determine the recommended Phase II dose of GSK2126458 based on safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary evidence of clinical activity. Secondary objectives are to characterize the pharmacokinetics of GSK2126458; and to explore relationships between GSK2126458 pharmacokinetics, pharmacodynamics, response prediction biomarkers and clinical endpoints.

Subjects with solid tumors or lymphoma will initially receive oral GSK2126458 daily for 28 consecutive days in each 28 day cycle. Subjects may be dosed once or twice a day or may be dosed on an intermittent schedule depending on the safety, pharmacokinetic and pharmacodynamic results that become available as the study progresses. The starting dose will be 0.1 mg once a day. Expansion of some cohorts will be conducted to test tumor pharmacodynamics, further explore the toxicity profile and to look for preliminary evidence of activity in subjects with tumors with PIK3CA mutations. The recommended Phase II dose will be the lowest dose explored (at or below MTD) that maintains biologic activity with an acceptable tolerability profile.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically- or cytologically- confirmed diagnosis of solid tumor malignancy, or lymphoma
  • Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale.
  • Female or male that is willing to take measures to avoid pregnancy in self or a partner, including abstinence, or double barrier method.
  • Adequate organ system function

Exclusion Criteria:

  • Use of an investigational anti-cancer medication within 28 days or 5 half-lives preceding the first dose of GSK2126458.
  • Chemotherapy within the last 3 weeks (6 weeks for prior nitrosourea or mitomycin C
  • Any major surgery, radiotherapy, or immunotherapy within the last 4 weeks.
  • Prior use of any PI3K inhibitor.
  • Current use of a prohibited medication or requires any of these medications during treatment with GSK2126458.
  • Presence of an active gastrointestinal disease or other condition known to interfere significantly with the absorption, distribution, metabolism, or excretion of drugs.
  • Unresolved toxicity greater than Grade 1 from previous anti-cancer therapy except alopecia.
  • QTc interval ≥ 480 msecs.
  • History of acute coronary syndromes; Class II, III, or IV heart failure; stroke or subarachnoid hemorrhage.
  • Systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg.
  • Previously diagnosed Type 1 diabetes mellitus. Subjects with Type 2 diabetes are prohibited in the dose escalation part of the study.
  • Symptomatic or untreated leptomeningeal or brain metastases.
  • Primary malignancy of the central nervous system.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00972686

Locations
United States, California
GSK Investigational Site
San Francisco, California, United States, 94115
United States, New Jersey
GSK Investigational Site
New Brunswick, New Jersey, United States, 08901
United States, North Carolina
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599-7600
United States, Texas
GSK Investigational Site
Dallas, Texas, United States, 75246
GSK Investigational Site
Houston, Texas, United States, 77030
United States, Utah
GSK Investigational Site
Salt Lake City, Utah, United States, 84112-5550
United States, Washington
GSK Investigational Site
Seattle, Washington, United States, 98109
Netherlands
GSK Investigational Site
Amsterdam, Netherlands, 1066 CX
GSK Investigational Site
Utrecht, Netherlands, 3584 CX
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00972686     History of Changes
Other Study ID Numbers: 112826
Study First Received: September 3, 2009
Last Updated: February 26, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
solid tumors
lymphoma
Phosphoinositide 3-kinase inhibitor

ClinicalTrials.gov processed this record on March 03, 2015